Avero Diagnostics

Ares Genetics - a Vienna based startup - is revolutionizing how we address the global challenge of antimicrobial resistance (AMR).

To enable better infection control and more targeted patient care, Ares Genetics aims to provide unprecedented insight into AMR through next generation sequencing (NGS) and artificial intelligence (AI) powered solutions.
Innovative machine learning driven bioinformatics and the extensively curated ARESdb database comprehensively detect and interpret the genetic profile of pathogens.
Unlike conventional molecular assays, Ares Genetics solutions not only detect AMR markers but shed light on prevalence and diagnostic performance for these markers and predict how pathogens will respond to therapy.

Imprint: https://www.ares-genetics.com/imprint

Quality Assistance S.A. is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products.

We assist our clients from candidate selection, through non-clinical and clinical studies, to marketing authorisation, using our state-of-the-art, product-dedicated expertise in analytical sciences.

For each customer and each project, we design customised solutions, define analytical protocols, develop and validate specific new analytical methods and perform characterisation, stability, pharmacokinetic, biomarker and immunogenicity studies as well as batch release testing, in order to evaluate the Quality, Safety and Efficacy of the given drugs.

Quality Assistance S.A. is an expert for the development of:
- Biologics (monoclonal antibodies, ADCs, proteins)
- New Chemical Entities, oligonucleotides, peptides
- Nanomedicine products
- Vaccines
- Cell-Based and Gene Therapy Medicinal Products

The company holds a unique position on the market with:
All its laboratories on one site (Donstiennes, Belgium)
- Bioanalysis (PK/TK/Immuno)
- Bioassays
- Biochemistry
- Chromatography
- Elemental Impurities
- Mass Spectrometry
- Microbiology
- Molecular Biology
- Protein Characterisation
200 highly qualified professionals
more than 35 years’ expertise at the forefront of analytical sciences.

Our core competencies are:
QUALITY (CMC)
- Development and validation of analytical methods
- Characterisation
- Stability studies
- Batch (release) testing
SAFETY/EFFICACY (Bioanalysis)
- Development and validation of bioanalytical methods
- PK/TK studies
- Immunogenicity studies
- Biomarker studies

The Quality Assistance environment is GMP, GLP and GCLP/GCP compliant.

Visit www.quality-assistance.com for more information

GEM FORLAB gives continuity to the experience of ABLE Biosciences as a global provider of scientific technology and services to the Life Science industry. It delivers solutions to companies of all size and shapes.
GEM FORLAB performs its activities by means of three technology areas:
Organic Chemistry
Mass Spectrometry & Proteomics
Cell and Molecular Biology & Immunoassay

ABLE Biosciences is the Test Facility GLP certified for small and large molecules quantitative analysis in biological matrices by means of Mass Spectrometry, Immunometric assays and qPCR and it is included in OsSC register of Private Laboratories qualified to perform analysis on samples derived from drug clinical trials (phase I-II-III) in compliance with GCP.

The Chemistry Unit provides all essential components for early drug discovery such as synthesis of chemical intermediates, process impurities, reference compounds, drug metabolites, and pro-drug; lead generation and optimization; bioconjugate chemistry; targeted molecules for MRI and others Molecular Imaging techniques.

AcceGen Biotech proudly develops innovative technologies for the pharmaceutical, biotech and specialty ingredients markets. We are committed to supplying the best products and services with global manufacturing, development expertise and advanced technologies to enhance the overall quality of life.

AcceGen Biotech developed significant expertise in cell and genomic research. We provide a variety of high-quality human/animal cells, cell media/kits, cell-derived molecular biology products, gene-based assay kits, Clones, Fish probes and Sequencing products for research use.

AcceGen Biotech offers custom cell line generation, microRNA sponges and microRNA Agomir/Antagomir services to simplify the gene research. The aim is to accelerate scientific discovery related to genetic analysis available to academic researchers as well as commercial enterprises.

AcceGen Biotech has permanent facilities in Fairfield (New Jersey). We take care of our customers and their global, regional or local requirements. We welcome potential partners and distributors to explore our business all over the world.

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.

MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.

Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free.

Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.

For view our social media policies, please visit https://agendia.com/legal-compliance/